The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Diagnostic Criteria, Phenotypes and Epidemiology of Autoimmune Encephalitis: Divyanshu Dubey, MBBSMay 7th 2023
The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]
Intrathecal Mesenchymal Stem Cell-Neural Progenitor Therapy Shows Therapeutic Response in Subgroups of Progressive MSMay 6th 2023
In a subgroup of individuals with secondary progressive MS, 50% of patients on mesenchymal stem cell-neural progenitor therapy improved muscle strength compared with 33% of those on placebo.
Evolving Landscape of Pediatric Neurology: Erika Fullwood Augustine, MD, MSMay 5th 2023
The associate chief science officer at Kennedy Krieger Institute shared thoughts on the state of pediatric neurology and the significance of being named winner of the Sydney Carter Award. [WATCH TIME: 3 minutes]
Recognizing Symptoms and Causes of Rapidly Progressive Dementia: Gregory Day, MD, MSc, MSCI, FAANMay 5th 2023
The neurologist at Mayo Clinic in Jacksonville Florida provided perspective on his talk given at the 2023 AAN annual meeting on rapidly progressive dementia. [WATCH TIME: 6 minutes]
Episode 88: 2023 AAN Annual Meeting HighlightsMay 5th 2023
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Michael H. Barnett, MBBS, PhD, FRACP; Nancy R. Foldvary-Schaefer, DO, FAAN; Sean J. Pittock, MD; Katherine W. Turk, MD; Erika U. Augustine, MD, MS; Jeffrey M. Statland, MD; and Chian-Chun Chiang, MD. [LISTEN TIME: 41 minutes]
Combination of Cipaglucosidase Alfa and Miglustat Shows Sustained Motor and Respiratory Function in Pompe DiseaseMay 4th 2023
After 48 months of follow up, cipaglucosidase alfa/miglustat in cohorts of ambulatory patients with Pompe disease had an overall safety profile similar to the approved enzyme replacement therapy.
Using Large-Scale Data, AI to Assess Effective Migraine Treatment Options: Chia-Chun Chiang, MDMay 4th 2023
The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]
Investigational Agent ALXN1840 Demonstrates Superior Efficacy to Standard of Care in Wilson DiseaseMay 4th 2023
Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.
Subgroup Analyses of Ravulizumab Demonstrates Effectiveness Across Patient Populations: Michael Levy, MD, PhDMay 4th 2023
The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Remote Electrical Neuromodulation Displays Superiority in Significantly Reducing Migraine DaysMay 3rd 2023
Presented at the 2023 AAN Annual Meeting, remote electrical neuromodulation demonstrated itself as an effective and safe treatment for the prevention of migraine when applied every other day.
Cenobamate as a Promising Treatment for Patients With Epilepsy: William E. Rosenfeld, MD, FAAN, FAESMay 3rd 2023
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Building a Neurology Space Inclusive of Diversity and Equity: Daniel Correa, MD, MScMay 3rd 2023
The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]
AAN Annual Meeting 2023: Top Expert InterviewsMay 2nd 2023
A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.
Serial Assessments Used in Groundbreaking Brain Study: Imad Najm, MDMay 2nd 2023
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]
Recombinant Human Growth Hormone, Testosterone Improves Ambulation, Disease Burden in Facioscapulohumeral Muscular DystrophyMay 2nd 2023
Total disease burden, measured by the Facioscapulohumeral Muscular Dystrophy Health Index, was reduced by 19% over a 24-week period on recombinant human growth hormone.
Future Research Directions for DCTclock and the Potential to Predict Alzheimer Biomarkers: Ali Jannati, MD, PhDMay 2nd 2023
The manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]
A Comprehensive Analysis of Stroke Prevalence Among Adults in the United States: Wells Andres, MDMay 1st 2023
The neurology resident from the University of Pennslyvania talked about stroke prevalence in the United States between 1999 and 2018 as part of a presentation at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Initiating Difficult Conversations With Patients Based on Hard Data: Daniel Ontaneda, MD, PhDApril 30th 2023
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University provided commentary on the need for clinicians to be transparent with patients with MS about potential differences in disease course. [WATCH TIME: 3 minutes]
ANX005 Demonstrates Safety in Huntington Disease, With Improvements Found in Subgroups of PatientsApril 29th 2023
In a subgroup of individuals with Huntington disease with high baseline C4a/C4 levels, treatment with ANX005 resulted in significant improvement in composite Unified Huntington’s Disease Rating Scale across all timepoints.
Efforts to Grow Neurology and Attract Young Medical Professionals to the Field: John Greenfield, MD, PhDApril 28th 2023
The president elect of the Association of University Professors of Neurology discussed the benefits of working in neurology and the ways to not only attract new clinicians, but keep those already in the field. [WATCH TIME: 3 minutes]
Clinical Research in ALS, the Potential of CNM-Au8 in the Care Landscape: James Berry, MD, MPHApril 28th 2023
The director of the Massachusetts General Hospital ALS Care Center discussed the importance of effective disease-modifying therapies for ALS and the potential of CNM-Au8 in the management of the disease. [WATCH TIME: 2 minutes]
Pridopidine Shows Clinically Meaningful Results in Huntington Disease for Patients Not on Neuroleptics, Chorea MedicationsApril 28th 2023
Q-Motor, an objective measure of motor function, showed robust beneficial effects for individuals treated with pridopidine in PROOF-HD at various time points.